Barriers to the Use of Personalized Medicine in Breast Cancer
- 1 July 2012
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Oncology Practice
- Vol. 8 (4), e24-e31
- https://doi.org/10.1200/jop.2011.000448
Abstract
Poorly coordinated diagnostic testing and the current oncology reimbursement model are barriers to the use of genomic and molecular diagnostic tests in cancer care.Keywords
This publication has 45 references indexed in Scilit:
- Improving Modern Cancer Care Through Information TechnologyAmerican Journal of Preventive Medicine, 2011
- Underutilization of BRCA1/2 testing to guide breast cancer treatment: Black and Hispanic women particularly at riskGenetics in Medicine, 2011
- Cancer's Next FrontierJAMA, 2010
- Opportunities for Research and NIHScience, 2010
- Three Changes for Affordable Care: One Payer's Wish ListJournal of Oncology Practice, 2009
- Postal survey of physicians and laboratories: Practices and perceptions of molecular oncology testingBMC Health Services Research, 2009
- A Health Services Research Agenda for Cellular, Molecular and Genomic Technologies in Cancer CarePublic Health Genomics, 2009
- Closing the Evidence Gap in the Use of Emerging Testing Technologies in Clinical PracticeJAMA, 2008
- American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast CancerJournal of Clinical Oncology, 2007
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004